Alector, Inc. (NASDAQ:ALEC) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET

Company Participants

Katie Hogan – Senior Director-Corporate Communications and Investor Relations
Arnon Rosenthal – Co-Founder and Chief Executive Officer
Sara Kenkare-Mitra – President and Head-Research and Development
Gary Romano – Chief Medical Officer
Marc Grasso – Chief Financial Officer

Conference Call Participants

Michael Reid – Morgan Stanley
Carter Gould – Barclays
Tom Shrader – BTIG
Sarah Schram – William Blair & Company
Ananda Ghosh – H.C. Wainwright & Company
Graig Suvannavejh – Mizuho Securities
Corinne Jenkins – Goldman Sachs

Operator

Good afternoon, ladies and gentlemen, and welcome to the Alector Second Quarter and Midyear 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, this conference call is being recorded.

I would now like to turn the call over to Katie Hogan, Senior Director of Corporate Communications and Investor Relations. Please go ahead.

Katie Hogan

Thank you, operator, and hello, everyone. Earlier this afternoon, we released our financial results for the second quarter 2024. The press release is available on our website at www.alector.com, and our 10-Q was filed with the Securities and Exchange Commission this afternoon. Joining me on the call today are Dr. Arnon Rosenthal, Co-Founder and CEO; Dr. Sara Kenkare-Mitra, President and Head of Research and Development; Dr. Gary Romano, Chief Medical Officer; and Dr. Marc Grasso, Chief Financial Officer.

After our formal remarks, we'll open the call for Q&A. I'd like to note that during this call, we'll be making a number of forward-looking statements. Please take a moment to review our slide on the webcast, which contains our forward-looking statement disclosure and we also encourage you to review our SEC filings for more information.

I would now like to turn the call over to Arnon Rosenthal, Chief Executive Officer. Arnon?

Arnon Rosenthal

Thank you, Katie. Good afternoon, everyone. We appreciate you joining our conference call today. I'll start by highlighting Alector's key initiatives during the first half of 2024. Then I'll invite Gary to discuss our later stage clinical programs. Next, Sara will share the progress we believe we have achieved with Alector Brain Carrier, our proprietary versatile blood-brain barrier technology platform. Afterwards, Marc will provide an update on our financial results and milestone outlook.

During the first half of 2024, we remain committed to advancing our maturing pipeline and are setting the stage for a transformative period ahead. Specifically, we continue to prepare for the data readout from the AL002 Phase 2 trial INVOKE-2 expected in Q4. AL002 our novel TREM2 agonist aims to enhance TREM2 signaling and activate the healthy and beneficial role that microglia play in the setting of neurodegenerative diseases.